Orphan Drugs

Executive Summary

Orphan drug submissions are assessed by CADTH through the CDR or pCODR, as there are no orphan drug-specific committees/processes. However, there are specific incentives, both financial and non-financial for manufacturers to launch their orphan drugs nationally. Currently, there are no accelerated marketing authorisation pathways available specifically for orphan drugs.